Health In Tech Inc

Health In Tech Inc operates with a market capitalization of $80.64 million and a price-to-book ratio of 13.02, indicating a premium valuation relative to its book value. The company's liquidity position is characterized by $1.36 million in cash and equivalents, but its operating cash flow is negative at -$680,210, and its net cash position is negative after subtracting total debt. The debt-to-equity ratio of 0.29 suggests a relatively conservative capital structure, with total liabilities of $4.25 million against total equity of $6.19 million.

Profitability metrics reveal a return on equity (ROE) of 1.62% and a return on assets (ROA) of 0.96%, both below the typical thresholds for performance in the insurance industry. The company's operating income of $332,420 and net income of $100,540 are modest relative to its revenue of $5.12 million, indicating a low-margin business model. Gross profit of $4.14 million represents 80.8% of revenue, but operating expenses consume a significant portion of this, leaving a narrow operating margin of 6.5%.

Geographically and segment-wise, the company's exposure is not disclosed in the available data, but its revenue concentration is not explicitly stated. Given the nature of the insurance industry, it is likely that the company's revenue is diversified across multiple lines of insurance products and geographic regions. However, without specific segment data, it is difficult to assess the degree of concentration risk.

The company's growth trajectory is not clearly defined in the available data, but its current financial performance suggests a stable but low-growth business. The operating cash flow is negative, and capital expenditures of -$133,390 indicate a reduction in investment in physical assets. Analysts have assigned a mean price target of $4.25, with a median of $4.25 and a high of $4.50, suggesting a potential upside of 244% from the current market price of $1.23. However, the mean recommendation of 2.00 (on a scale of 1 to 5) indicates a "buy" rating, with no strong buy recommendations.

Risk factors include a medium liquidity risk due to the negative operating cash flow and a negative net cash position after debt. The company's dilution risk is assessed as low, with no near-term pressure expected. The risk assessment also notes that the company's net cash is negative after subtracting total debt, which could impact its ability to fund operations without external financing.

Recent events and filings do not provide specific details on material developments, but the company's financial performance and analyst ratings suggest a cautious outlook. The absence of strong buy recommendations and the high price targets indicate that while analysts see potential, they are not overly optimistic about the company's near-term performance.

Health In Tech Inc (HIT.O) has recorded a notable addition to its shareholder base, marking a significant development for the company. As of March 31, 2026, investor ID 471 acquired a position of 183,325 shares, valued at approximately $0.27 million. This transaction represents a weight of roughly 0.0017% in the investor's portfolio and was detected on June 20, 2026. This activity is particularly relevant as it constitutes the first analysis available for this ticker, meaning there is no prior basis for computing delta changes in shareholder composition. The emergence of this new holder provides the initial data point for tracking institutional or significant investor interest in Health In Tech Inc. The significance of this change lies in the context of the company's current profile. Health In Tech Inc currently reports zero officers, zero analyst coverage, and no index memberships. The entry of a new holder into a company with such limited public market infrastructure may signal early-stage interest or specific strategic positioning by the investor. With only six top holders identified in total, the addition of investor ID 471 contributes to the sparse ownership structure of Health In Tech Inc. This development warrants monitoring to see if it precedes further analyst coverage or corporate governance updates, given the current absence of these standard market indicators.

Analysts project 272.8% upside to a mean price target of $4.25, signaling strong potential for significant share price appreciation.

The company maintains a low leverage band with a debt-to-equity ratio of 0.35, indicating a conservative capital structure.

Operating margin of 6.49% matches the cohort median, demonstrating competitive operational efficiency within the life and health insurance sector.

Revenue reached $33.3 million in FY0, showing substantial scale compared to $5.8 million in FY-3 despite recent volatility.

The firm generated positive net income of $1.28 million in FY0, confirming its ability to achieve profitability in recent periods.

Return on equity of 1.62% sits in the bottom quartile of the cohort, indicating poor capital efficiency relative to peers.

Cash conversion of -6.77 ranks in the bottom quartile, suggesting significant challenges in generating cash from operations.

Net margin of 1.96% falls below the cohort median of 3.84%, reflecting weaker bottom-line performance than industry peers.

Revenue $7.5M, +53,1% YoY; Operating income +46,0% YoY.

• ▍Revenue $7.5M, +53,1% YoY
• ▍Operating income +46,0% YoY
• ▍Net income −109,9% YoY
• ▍Net margin -4.0%

Revenue $8.5M, +90,4% YoY; Operating income +12,4% YoY.

• ▍Revenue $8.5M, +90,4% YoY
• ▍Operating income +12,4% YoY
• ▍Net income +20,2% YoY
• ▍Net margin 5.3%

Revenue $9.3M, +86,2% YoY; Operating income +35,5% YoY.

• ▍Revenue $9.3M, +86,2% YoY
• ▍Operating income +35,5% YoY
• ▍Net income +86,6% YoY
• ▍Net margin 6.8%

Revenue $8.0M, +56,4% YoY; Operating income +44,6% YoY.

• ▍Revenue $8.0M, +56,4% YoY
• ▍Operating income +44,6% YoY
• ▍Net income +395,9% YoY
• ▍Net margin 6.2%

Revenue $33.3M, +71,0% YoY; Operating income +54,4% YoY.

• ▍Revenue $33.3M, +71,0% YoY
• ▍Operating income +54,4% YoY
• ▍Net income +90,7% YoY
• ▍Net margin 3.8%